Logo image of LSTA

LISATA THERAPEUTICS INC (LSTA) Stock Fundamental Analysis

USA - NASDAQ:LSTA - US1280583022 - Common Stock

2.37 USD
-0.06 (-2.47%)
Last: 10/10/2025, 8:41:25 PM
2.35 USD
-0.02 (-0.84%)
After Hours: 10/10/2025, 8:41:25 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LSTA. LSTA was compared to 536 industry peers in the Biotechnology industry. LSTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LSTA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LSTA has reported negative net income.
LSTA had a negative operating cash flow in the past year.
In the past 5 years LSTA always reported negative net income.
LSTA had a negative operating cash flow in each of the past 5 years.
LSTA Yearly Net Income VS EBIT VS OCF VS FCFLSTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -75.21%, LSTA is not doing good in the industry: 65.92% of the companies in the same industry are doing better.
With a Return On Equity value of -89.99%, LSTA perfoms like the industry average, outperforming 48.79% of the companies in the same industry.
Industry RankSector Rank
ROA -75.21%
ROE -89.99%
ROIC N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
LSTA Yearly ROA, ROE, ROICLSTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

LSTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSTA Yearly Profit, Operating, Gross MarginsLSTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

6

2. Health

2.1 Basic Checks

LSTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LSTA has been increased compared to 1 year ago.
LSTA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LSTA Yearly Shares OutstandingLSTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
LSTA Yearly Total Debt VS Total AssetsLSTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -29.73, we must say that LSTA is in the distress zone and has some risk of bankruptcy.
LSTA has a Altman-Z score of -29.73. This is amonst the worse of the industry: LSTA underperforms 89.20% of its industry peers.
There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.73
ROIC/WACCN/A
WACC9.47%
LSTA Yearly LT Debt VS Equity VS FCFLSTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

LSTA has a Current Ratio of 5.77. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LSTA (5.77) is better than 61.64% of its industry peers.
A Quick Ratio of 5.77 indicates that LSTA has no problem at all paying its short term obligations.
LSTA has a Quick ratio of 5.77. This is in the better half of the industry: LSTA outperforms 61.83% of its industry peers.
Industry RankSector Rank
Current Ratio 5.77
Quick Ratio 5.77
LSTA Yearly Current Assets VS Current LiabilitesLSTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.23% over the past year.
EPS 1Y (TTM)13.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

LSTA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.18% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.37%
EPS Next 2Y25.07%
EPS Next 3Y17.28%
EPS Next 5Y12.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSTA Yearly Revenue VS EstimatesLSTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2022 2024 2027 2028 2029 2030 2031 50M 100M 150M 200M
LSTA Yearly EPS VS EstimatesLSTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LSTA. In the last year negative earnings were reported.
Also next year LSTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSTA Price Earnings VS Forward Price EarningsLSTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSTA Per share dataLSTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

LSTA's earnings are expected to grow with 17.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.07%
EPS Next 3Y17.28%

More info and screens

0

5. Dividend

5.1 Amount

LSTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LISATA THERAPEUTICS INC

NASDAQ:LSTA (10/10/2025, 8:41:25 PM)

After market: 2.35 -0.02 (-0.84%)

2.37

-0.06 (-2.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06
Inst Owners8.94%
Inst Owner Change0%
Ins Owners7.22%
Ins Owner Change0%
Market Cap20.76M
Analysts82.22
Price Target21.08 (789.45%)
Short Float %0.22%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.41%
Min EPS beat(2)-1.74%
Max EPS beat(2)18.55%
EPS beat(4)3
Avg EPS beat(4)17.18%
Min EPS beat(4)-1.74%
Max EPS beat(4)29.05%
EPS beat(8)7
Avg EPS beat(8)20.12%
EPS beat(12)10
Avg EPS beat(12)-44.54%
EPS beat(16)13
Avg EPS beat(16)-29.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.55%
EPS NY rev (1m)5.52%
EPS NY rev (3m)11.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.4
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 0.99
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-1.88
FCFYN/A
OCF(TTM)-1.87
OCFYN/A
SpS0.12
BVpS2.4
TBVpS2.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.21%
ROE -89.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.77
Quick Ratio 5.77
Altman-Z -29.73
F-Score4
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.48%
EPS Next Y5.37%
EPS Next 2Y25.07%
EPS Next 3Y17.28%
EPS Next 5Y12.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.04%
EBIT Next 3Y-10.73%
EBIT Next 5Y-1.14%
FCF growth 1Y28.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.21%
OCF growth 3YN/A
OCF growth 5YN/A